Nectin4 was discovered as an adhesion molecule belonging to the nectin family of the immunoglobulin superfamily (Reymond et al., 2001), and was then recognized as being highly expressed in clinically relevant cancer indications, including bladder and urothelial cancers, pancreatic carcinoma, some breast cancers, including the undruggable triple negative breast cancer, cervical cancer, lung carcinomas and, recently, melanoma (Deng et al., 2019; Chatterjee et al., 2021; Heath and Rosenberg, 2021; Tanaka et al., 2021; Bouleftour et al., 2022; Hashimoto et al., 2022). This evidence concerns the gene NECTIN4 and cancer.